At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ENVB Enveric Biosciences
Pre-Market Trading 05-10 07:50:37 EDT
0.9200
-0.0600
-6.12%
盘前0.8700
-0.0500-5.43%
07:28 EDT
High0.9900
Low0.9010
Vol948.84K
Open0.9044
D1 Closing0.9800
Amplitude9.08%
Mkt Cap6.71M
Tradable Cap6.60M
Total Shares7.29M
T/O884.55K
T/O Rate13.23%
Tradable Shares7.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Enveric Biosciences Announces Signing Of Non-Binding Term Sheet With Undisclosed Licensee For Exclusive License To Patented Methods Of Treating Breast And Other Cancers Using Cannabinoids
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
BRIEF-Enveric Biosciences Signs Non-Binding Term Sheets To Pursue The Exclusive Out-Licensing Of New Chemical Entities For Pharmaceutical And Non-Pharmaceutical Applications In Joint Disease
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.